CCO Independent Conference Coverage

CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

December 13-16, 2007 | San Antonio, Texas

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Early Breast Cancer: Endocrine Therapy

Track 1 of 4
Capsule Summaries
Expert Analysis
CCO Expert Recap
CCO Slideset

Faculty:

Harold J. Burstein, MD, PhDPeter Ravdin, MD, PhDEric P. Winer, MD
  • Harold J. Burstein, MD, PhD
  • Peter Ravdin, MD, PhD
  • Eric P. Winer, MD

Early Breast Cancer: Chemotherapy and Targeted Agents

Track 2 of 4
Capsule Summaries
Expert Analysis

Faculty:

Howard A. Burris III, MDWilliam J. Gradishar, MD, FACPEdith A. Perez, MD
  • Howard A. Burris III, MD
  • William J. Gradishar, MD, FACP
  • Edith A. Perez, MD

Metastatic Breast Cancer

Track 3 of 4
Capsule Summaries
Expert Analysis

Faculty:

Clifford A. Hudis, MDKathy D. Miller, MDJoyce O’Shaughnessy, MD
  • Clifford A. Hudis, MD
  • Kathy D. Miller, MD
  • Joyce O’Shaughnessy, MD

Prognosis and Prediction

Track 4 of 4
Capsule Summaries
Expert Analysis

Faculty:

Matthew Ellis, MD, PhDDaniel F. Hayes, MDHope S. Rugo, MD
  • Matthew Ellis, MD, PhD
  • Daniel F. Hayes, MD
  • Hope S. Rugo, MD

Expert Highlights

Daniel F. Hayes, MD headshot

Daniel F. Hayes, MD, discusses studies that focused on the benefits of tailoring patients to individualized therapy to be able to predict which patients will or will not benefit from chemotherapy or hormonal therapy. (5 minutes)

 Download Audio
Edith A. Perez, MD headshot

Edith A. Perez, MD, reviews studies that highlighted molecular profiling in estrogen receptor-positive disease to determine if patients will benefit from chemotherapy. She also comments on the use of targeted therapies in the adjuvant setting. (2 minutes)

 Download Audio
Peter Ravdin, MD, PhD headshot

Peter Ravdin, MD, describes the use of biomarkers and molecular tests and how those will help enhance clinical decisions for treating patients with early breast cancer. He also comments on the use of aromatase inhibitors in patients with early-stage breast cancer. (9 minutes)

 Download Audio
Clifford A. Hudis, MD headshot

Clifford A. Hudis, MD, highlights key studies including the promise of pharmacogenomics for patients with breast cancer in the metastatic setting. (4 minutes)

 Download Audio

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.